Comparing the Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists with Sodium-Glucose Cotransporter 2 Inhibitors for Obese Type 2 Diabetes Patients Uncontrolled on Metformin: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

<div>Forest plot for meta-analyses comparing the overall safety of GLP-1RAs with SGLT-2is. AEs leading to discontinuation includes injury, angioedema and infections, etc. AEs: adverse events, GLP-1RAs: glucagon-like peptide 1 receptor agonists, SGLT-2is: sodium-glucose cotransporter 2 inhibitors, CI: confidence interval.</div>

International Journal of Endocrinology

fig4

Figure 4

Figure 4: Comparing the Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists with Sodium-Glucose Cotransporter 2 Inhibitors for Obese Type 2 Diabetes Patients Uncontrolled on Metformin: A Systematic Review and Meta-Analysis of Randomized Clinical Trials 

Figure 4 | Comparing the Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists with Sodium-Glucose Cotransporter 2 Inhibitors for Obese Type 2 Diabetes Patients Uncontrolled on Metformin: A Systematic Review and Meta-Analysis of Randomized Clinical Trials 